Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/753
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Moban (Tablet)
|
| dailymed-instance:dosage |
Initial and maintenance doses of MOBAN should be individualized.<br/>Initial Dosage Schedule: The usual starting dosage is 50-75 mg/day.���Increase to 100 mg/day in 3 or 4 days.���Based on severity of symptomatology, dosage may be titrated up or down depending on individual patient response.���An increase to 225 mg/day may be required in patients with severe symptomatology.Elderly and debilitated patients should be started on lower dosage.<br/>Maintenance Dosage Schedule: 1. Mild-5 mg-15 mg three or four times a day.2. Moderate-10 mg-25 mg three or four times a day.3. Severe-225 mg/day may be required.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:boxedWarn... |
WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis���Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heartfailure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. MOBAN is not approved for the treatment of patients with dementia-related psychosis .
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
Molindone Hydrochloride
|
| dailymed-instance:fullName |
Moban (Tablet)
|
| dailymed-instance:indicatio... |
MOBAN is indicated for the management of schizophrenia. The efficacy of MOBAN in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized, acutely ill, schizophrenic patients as subjects.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Moban
|